Deal Watch: Shire, Allergan Move To Shore Up Core Franchises
Executive Summary
Bristol acquires Cardioxyl and its Phase II congestive heart failure candidate as the latest deal to firm up its specialty drug pipeline, while Sanofi inks a cancer immunotherapy deal with BioNTech and a pair of diabetes-related partnerships with Hanmi and Lexicon.
You may also be interested in...
Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact
Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.